Key result
Point-of-care Cholestech LDX testing shows excellent agreement with laboratory analysis for calculated CVD risk.
Why the study?
Following a Department of Health cardiovascular disease risk assessment initiative targeting health inequalities in ethnic minorities, vascular screening of South Asian subjects was conducted to evaluate the agreement between point of care testing and hospital laboratory measurements.
Does point of care testing using the Cholestech LDX analyser provide accurate lipid, glucose, and cardiovascular disease risk assessments compared to hospital laboratory venous analysis in South Asian individuals?
Cross-Sectional (n=406)
Yes
Does point of care testing using the Cholestech LDX analyser provide accurate lipid, glucose, and cardiovascular disease risk assessments compared to hospital laboratory venous analysis in South Asian individuals?
Answers are grounded in this paper and cite their sources.
Point of care testing using the Cholestech LDX analyser demonstrates high agreement with laboratory venous samples across multiple CVD risk calculators, supporting its use in NHS Health Checks for South Asian populations.
BACKGROUND: The Department of Health launched a cardiovascular disease risk assessment initiative with particular reference to reducing health inequalities in ethnic minorities. Collaboration between HEART UK, Royal Free Hampstead NHS Trust and Hindu Temples resulted in vascular screening in North London. METHODS: Subjects of South Asian origin were screened. A full lipid profile and glucose were measured using a point of care testing (POCT) Cholestech LDX analyser (LDX). Venous samples were analysed in our hospital laboratory. RESULTS: The results (215 men; 191 women) were divided into tertiles and Bland-Altman plots were used to assess agreement. At high-density lipoprotein cholesterol (HDL-C) concentrations < 1.0 mmol/L the LDX underestimated values by -0.2 mmol/L (P<0.0001). At HDL-C concentrations >1.3 mmol/L this bias disappeared. For total cholesterol the concentration-dependent negative bias was evident at concentrations of < 4.1 mmol/L (P < 0.0001). This bias was less evident at higher concentrations. A similar pattern was seen for low-density lipoprotein cholesterol. There were also small variations in glucose and triglyceride values. However, there was excellent agreement in calculated cardiovascular disease risk using kappa analysis for JBS2, QRISK2, ETHRISK and Framingham (κ = 0.86, 0.92, 0.94 and 0.88, respectively). This was a high-risk population since 9.7-19.4% had a ≥ 20% 10-y probability of a vascular event depending on the risk engine and assay method used. The corresponding values for intermediate risk (11-19%) were 18.6-25.7%. CONCLUSIONS: There was a minimum mismatch irrespective of the type of risk calculator used. POCT measurements are adequate for the National Health Service Health Check.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2011) conducted a cross-sectional in Cardiovascular disease risk assessment in South Asian individuals (n=406). Point of care testing (POCT) using Cholestech LDX analyser vs. Hospital laboratory venous sample analysis was evaluated on Agreement in calculated cardiovascular disease risk (JBS2, QRISK2, ETHRISK, Framingham) and lipid/glucose concentrations (κ = 0.86 to 0.94, p=<0.0001). Point of care testing via Cholestech LDX showed excellent agreement with laboratory venous analysis for calculated CVD risk.
Synapse has enriched 10 related papers. Consider them for comparative context: